Documentos relacionados

1. Berberine Effects in Pre-Fibrotic Stages of Non-Alcoholic Fatty Liver Disease-Clinical and Pre-Clinical Overview and Systematic Review of the Literature.
2. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
3. The Influence of Emodin Succinyl Ethyl Ester on Non-alcoholic Steatohepatitis Induced by a Diet High in Fructose, Cholesterol, and Fat in Mice.
4. Monkfish Peptides Mitigate High Fat Diet-Induced Hepatic Steatosis in Mice.
5. Integrated transcriptomic landscape of the effect of anti-steatotic treatments in high-fat diet mouse models of non-alcoholic fatty liver disease.
6. NLRP3 inflammasome inhibitor CY-09 reduces hepatic steatosis in experimental NAFLD mice.
7. En masse organoid phenotyping informs metabolic-associated genetic susceptibility to NASH.
8. Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice.
9. Impact of flaxseed supplementation on lipid profile and liver enzymes in patients with non-alcoholic fatty liver disease: Systematic review and meta-analysis of randomized controlled trials.
10. Kaempferol Alleviates Hepatic Injury in Nonalcoholic Steatohepatitis (NASH) by Suppressing Neutrophil-Mediated NLRP3-ASC/TMS1-Caspase 3 Signaling.